1. Home
  2. SRBK vs IPA Comparison

SRBK vs IPA Comparison

Compare SRBK & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRBK
  • IPA
  • Stock Information
  • Founded
  • SRBK 1887
  • IPA 1983
  • Country
  • SRBK United States
  • IPA United States
  • Employees
  • SRBK N/A
  • IPA N/A
  • Industry
  • SRBK
  • IPA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SRBK
  • IPA Health Care
  • Exchange
  • SRBK Nasdaq
  • IPA Nasdaq
  • Market Cap
  • SRBK 117.4M
  • IPA 98.9M
  • IPO Year
  • SRBK N/A
  • IPA 2017
  • Fundamental
  • Price
  • SRBK $14.92
  • IPA $2.17
  • Analyst Decision
  • SRBK
  • IPA Strong Buy
  • Analyst Count
  • SRBK 0
  • IPA 2
  • Target Price
  • SRBK N/A
  • IPA $4.00
  • AVG Volume (30 Days)
  • SRBK 31.0K
  • IPA 1.9M
  • Earning Date
  • SRBK 10-25-2025
  • IPA 09-24-2025
  • Dividend Yield
  • SRBK 1.34%
  • IPA N/A
  • EPS Growth
  • SRBK N/A
  • IPA N/A
  • EPS
  • SRBK 0.44
  • IPA N/A
  • Revenue
  • SRBK $31,833,000.00
  • IPA $17,744,713.00
  • Revenue This Year
  • SRBK N/A
  • IPA $18.76
  • Revenue Next Year
  • SRBK N/A
  • IPA $32.14
  • P/E Ratio
  • SRBK $33.93
  • IPA N/A
  • Revenue Growth
  • SRBK 39.53
  • IPA 0.01
  • 52 Week Low
  • SRBK $10.09
  • IPA $0.27
  • 52 Week High
  • SRBK $15.22
  • IPA $3.25
  • Technical
  • Relative Strength Index (RSI)
  • SRBK 56.99
  • IPA 51.05
  • Support Level
  • SRBK $14.82
  • IPA $1.80
  • Resistance Level
  • SRBK $15.11
  • IPA $2.00
  • Average True Range (ATR)
  • SRBK 0.19
  • IPA 0.28
  • MACD
  • SRBK -0.03
  • IPA -0.08
  • Stochastic Oscillator
  • SRBK 41.18
  • IPA 25.59

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

About IPA ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.

Share on Social Networks: